Aug 2026· Current Medical Science· 0 citations· 50 references
Medicine
TL;DR
Despite the proven success of preclinical studies on the delivery of migraine drugs loaded with nanocarriers loaded with antimigraine agents and delivered by the IN route, there is still a shortage in translating this success into the clinical stage.
Intranasal delivery is increasingly recognised as a promising strategy for direct drug transport to the brain via the nose-to-brain pathway, bypassing the blood-brain barrier and improving therapeutic efficacy. This approach has shown potential in the treatment of neurological disorders, including Alzheimer's disease,...
Intranasal drug delivery represents a rapidly evolving and promising platform for targeted CNS therapeutics, offering a non-invasive approach with improved patient compliance and enhanced brain targeting, with particular emphasis on emerging technologies designed to improve CNS targeting and therapeutic efficacy.
S. Chouhan, A. Parashar, Trapti Mahajan et al.· Current Pharmacology Reports· 0 citations
Clinical trials and translational evidence for intranasal PD therapies by treatment options and intent are summarized, highlighting key challenges in efficacy, pharmacokinetics, and safety.
E. Cherny, Tamara Minko· Pharmaceutics· 0 citations
NeuroAIDS refers to the spectrum of neuropsychiatric complications observed in approximately 30–50% of HIV/AIDS patients. Although the advent of antiretroviral therapy has reduced the severity of AIDS, mild cognitive deficits persist in nearly half of treated patients, highlighting limitations in central nervous system...
S. Taher, Khalid K. Al-kinani· Iraqi Journal of Pharmaceuti...· 0 citations
Overall, nanocarrier-assisted nose-to-brain drug delivery represents a transformative platform for the management of central nervous system disorders and has the potential to overcome the limitations of conventional drug delivery systems and improve therapeutic outcomes for a wide range of neurological diseases.
Alpana, H. Dewangan· Current Nanomedicine· 0 citations
Schizophrenia remains one of the most disabling mental disorders, and effective therapy is still limited by the difficulty of delivering drugs across the blood-brain barrier. Aripiprazole (Ari), a first-line atypical antipsychotic, exhibits restricted clinical performance due to poor solubility, extensive hepatic metab...
Rabab M Ibrahim, M. Teaima, M. el-Nabarawi et al.· Drug Delivery and Translatio...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
